HIV and HCV infection among injecting drug users

Mount Sinai Journal of Medicine

Volumn 67, Issue 5-6, 2000, Pages 423-428

  Hagan, Holly ^a,b   Des Jarlais, Don C ^c  

^a PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Epidemiology; HCV; HIV; Injection drug use; Substance abuse

Indexed keywords

COMPARATIVE STUDY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; METHODOLOGY; PATHOPHYSIOLOGY; PREVALENCE; PREVENTIVE HEALTH SERVICE; REVIEW; SUBSTANCE ABUSE; VIROLOGY;

HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; PREVALENCE; PREVENTIVE HEALTH SERVICES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0034293088     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Patrick DM, Strathdee SA, Archibald CP, et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS 1997; 8:437-445.
2. Chitwood DD, Griffin DK, Comerford M, et al. Risk factors for HIV-1 seroconversion among injection drug users: A case-control study. Am J Public Health 1995; 85:1538-1542.
3. Jose B, Friedman SR, Neaigus A, et al. Syringe-mediated drug-sharing (backloading): A new risk factor for HIV among injecting drug users. AIDS 1993; 7:1653-1660.
4. Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I. Front-loading: A risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS 1996; 10:311-317.
5. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr 1998; 18(Suppl):S6-S10.
6. van den Hoek JA, Coutinho RA, van Haastrecht HJ, et al. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988; 2:55-60.
7. Piconi S, Clerici M. Notes on the pathogenesis of human immunodeficiency virus infection. Ann Ist Super Sanita 1997; 33:219-223.
8. Phair JP. Determinants of the natural history of human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179(Suppl2):S384-S386.
9. Simonsen JN, Fowke KR, MacDonald KS, Plummer FA. HIV pathogenesis: Mechanisms of susceptibility and disease progression. Curr Opin Microbiol 1998; 1:423-429.
10. Lange J. Natural history of HIV disease and predictors of clinical outcome. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(Suppl):S43-S45.
11. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996; 275:1329-1334.
12. The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS 1992; 6:421-426.
13. Ronald PJ, Robertson JR, Elton RA. Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS 1994; 8:339-343.
14. Krol A, Flynn C, Vlahov D, et al. New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users. Drug Alcohol Depend 1999; 54:145-154.
15. Weber R, Ledergerber B, Opravil M, et al. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ 1990; 301:1362-1365.
16. Kak V, MacArthur RD, Crane LR. Treatment of HIV disease in the new millennium. Semin Thorac Cardiovasc Surg 2000; 12:140-144.
17. Erb P, Battegay M, Zimerli W, et al. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med 2000; 160:1134-1140.
18. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351:228-230.
19. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-1942.
20. The CASCADE Collaboration. Concerted Action on Seroconversion to AIDS and Death in Europe. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355:1158-1159.
21. Remien RH, Smith RA. HIV prevention in the era of HAART: Implications for providers. AIDS Read 2000; 10:247-251.
22. WHO Collaborative Study Group. An international comparative study of HIV prevalence and risk behaviour among drug injectors in 13 cities. Bull Narc 1993; 45:19-46.
23. Stimson GV. The global diffusion of injecting drug use: Implications for human immunodeficiency virus infection. Bull Narc 1993; 45:3-17.
24. Wodak A. Harm reduction: Australia as a case study. Bull N Y Acad Med 1995; 72:339-347.
25. Stimson GV. AIDS and injecting drug use in the United Kingdom, 1987-1993: The policy response and the prevention of the epidemic. Soc Sci Med 1995; 41:699-716.
26. Rhodes TJ, Bloor MJ, Donoghoe MC, et al. HIV prevalence and HIV risk behavior among injection drug users in London and Glasgow. AIDS Care 1993; 5:413-425.
27. Hagan H, Des Jarlais DC, Purchase D, et al. An interview study of participants in the Tacoma syringe exchange. Addiction 1993; 88:1691-1697.
28. Ljungberg B, Christensson B, Tunving K, et al. HIV prevention among injection drug users: Three years of experience from a syringe exchange in Sweden. J Acquir Immune Defic Syndr 1991; 4:890-895.
29. Crofts N, Aitken CK. Incidence of blood-borne viral infection and risk behaviours in a cohort of injection drug users in Victoria, 1990-1995. Med J Aust 1997; 167:17-20.
30. Wiebel WW, Jimenez A, Johnson W, et al. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: A four-year prospective study. J Acquir Immun Defic Syndr Hum Retrovirol 1996; 12:282-289.
31. Choopanya K, Vanischeni S, Des Jarlais DC, et al. Risk factors and HIV seropositivity among injection drug users in Bangkok. AIDS 1991; 5:1509-1513.
32. van Ameijden EJC, van den Hoek JAR, Mientjes GH, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993; 9:255-262.
33. Des Jarlais DC. The 1993 Okey Memorial Lecture. Cross-national studies of AIDS among injecting drug users. Addiction 1994; 89:383-392.
34. van Ameijden EJ, Coutinho RA. Maximum impact of HIV prevention measures targeted at injection drug users. AIDS 1998; 12:625-632.
35. Levine OS, Vlahov D, Brookmeyer R, et al. Differences in the incidence of hepatitis B and HIV infections among injection drug users. J Infec Dis 1996; 173:579-583.
36. Zheng X, Tian C, Choi KH, et al. Injecting drug use and HIV infection in SW China. AIDS 1994; 8:1141-1147.
37. Poshyachinda V. Drug injecting and HIV infection among the population of drug abusers in Asia. Bull Narc 1993; 45:77-90.
38. Dehne KL, Khodakevich L, Hamers FF, Schwartlander B. The HIV/AIDS epidemic in eastern Europe: Recent patterns and trends and their implications for policy-making AIDS 1999; 13:741-749.
39. Celentano DD, Hodge MJ, Razak MH, et al. HIV-1 incidence among opiate users in Northern Thailand. Am J Epidemiol 1999; 149:558-564.
40. Des Jarlais DC, Friedman SR, Sotheran JL. Continuity and change within an HIV epidemic: Injecting drug users in New York City, 1984 through 1992. JAMA 1994; 271:121-127.
41. Burns SM, Brettle RP, Gore SM, et al. The epidemiology of HIV infection in Edinburgh related to the injecting of drugs: An historical perspective and new insight regarding the past incidence of HIV infection derived from retrospective HIV antibody testing of stored samples of serum. J Infect 1996; 3:253-262.
42. Seeff LB. The natural history of viral hepatitis, type C. Semin Gastrointest Dis 1995; 6:20-27.
43. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:909-914.
44. Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992; 89:3468-3472.
45. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258:135-140.
46. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343:388-390.
47. Pape GR, Gerlach TJ, Diepolder HM, et al. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999; 6 Suppl 1:36-40.
48. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
49. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: A case-control study. Ann Intern Med 1992; 116:97-102.
50. Yu MC, Tong MJ, Corsaget P, et al. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990; 82:1038-1041.
51. Rodger AJ, Thomson JA, Thompson SC, et al. Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: Results of a pilot study. J Gastroenterol Hepatol 1999; 14:269-273.
52. Imperial JC. Natural history of chronic hepatitis B and C. J Gastroenterol Hepatol 1999; 14(Suppl):S1-S5.
53. Tagger A, Donato F, Ribero ML, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Int J Cancer 1999; 81:695-699.
54. Gerotto M, Sullivan DG, Polyak SJ, et al. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. J Virol 1999; 73:7241-7247.
55. Christie JM, Chapman RW. Combination therapy for chronic hepatitis C: Interferon and ribavirin. Hosp Med 1999; 60:357-361.
56. Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference. J Gastroenterol Hepatol 1999; 14(Suppl):S12-S18.
57. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subs Use Misuse 1998; 33:1197-1212.
58. Mele A, Biancolilli V, Dargenio P, Sagliocca L. Considerations on markers of hepatitis B, C and HIV as indicators of risk behavior in intravenous drug users. J Public Health Med 1993; 15:112.
59. Chamot E, de Saussure Ph, Hirschel B, et al. Incidence of hepatitis B, hepatitis C, and HIV infections among drug users in a methadone maintenance programme. AIDS 1992; 6:431-432.
60. Hagan H, McGough J, Thiede H, et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149:203-213.
61. Crofts N, Stewart T, Hearne P, et al. Spread of blood-borne viruses among Australian prison entrants. BMJ 1995; 310:285-288.
62. Anderson RA, May RA. Infectious diseases in humans. London: Oxford University Press; 1995.
63. Gerberding J. Management of occupational exposures to blood-borne viruses. N Engl J Med 1995; 332:444-451.
64. Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence in injecting drug users in New York City: Evidence for a declining epidemic. Am J Public Health 2000; 90:352-359.
65. Van Ameijden E, Notenboom J, Langendan MW. Residual injecting risk in Amsterdam is often deliberate and prevention of sex risk gains importance. Proc Int Conf AIDS 1998; 12:380 (Abstract no. 23193).
66. Paone D, Des Jarlais DC, Caloir S, et al. Continued risky injection subsequent to syringe exchange use among injection drug users in New York City. AIDS Educ Prev 1997; 9:505-510.
67. Mann JM. AIDS and the future of public health. Proc Int Conf AIDS 1996; 2:244 (Abstract no. Th.D.350).
68. Koester SK, Hoffer L. "Indirect sharing": Additional HIV risks associated with drug injection. AIDS Public Policy J 1994; 9:100-105.
69. Cohen J. The scientific challenge of hepatitis C. Science 1999; 285:26-30.
70. Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995; 274:1226-1231.
71. Wodak AI, Crofts N. Once more into the breach: Preventing HCV transmission in injection drug users. Addiction 1996; 91:84-84.
72. Hagan H, Des Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and C among participants in a syringe exchange program. Am J Public Health 1995; 85:1531-1537.
73. Crofts N, Nigro L, Oman K, et al. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997; 92:999-1005.